Kurs & Likviditet
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Bioteknik |
2022-02-08 07:00:03
Bergen, Norway,8 February 2022?-BerGenBioASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical need,will be announcing its results for thefourthquarter
2021 onWednesday 16 February 2022.
A briefing by BerGenBio's senior management team will take place at 10:00 am CET
via a webcast presentation, followed by a Q&A session.
The live webcast link will be available at www.bergenbio.comin the
Investors/Financial Reports section. A recording will be available shortly after
the webcast has finished.
Thefourthquarter 2021 report and presentation will be available on the Company's
website in the Investors/Financial Reports section from 7:00 am CET the same
day.
-Ends-
Contacts
Martin Olin
Chief Executive Officer, BerGenBio ASA
ir@bergenbio.com
Rune Skeie
Chief FinancialOfficer, BerGenBio ASA
rune.skeie@bergenbio.com
International Media Relations
Mary-Jane Elliott, Chris Welsh, Lucy Featherstone
ConsiliumStrategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700
AboutBerGenBioASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company's proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in cancer and COVID
-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is
undergoing phase I clinical testing. In parallel, BerGenBio is developing a
potential companion diagnostic test to identify patient populations most likely
to benefit from AXL inhibition: this is expected to facilitate more efficient
registration trials supporting a precision medicine-based commercialisation
strategy.
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit? www.bergenbio.com
Forward looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies, and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.